<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Can J Kidney Health Dis</journal-id><journal-id journal-id-type="iso-abbrev">Can J Kidney Health Dis</journal-id><journal-id journal-id-type="publisher-id">CJK</journal-id><journal-id journal-id-type="hwp">spcjk</journal-id><journal-title-group><journal-title>Canadian Journal of Kidney Health and Disease</journal-title></journal-title-group><issn pub-type="epub">2054-3581</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage CA: Los Angeles, CA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29326843</article-id><article-id pub-id-type="pmc">5757433</article-id><article-id pub-id-type="doi">10.1177/2054358117749532</article-id><article-id pub-id-type="publisher-id">10.1177_2054358117749532</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Risk of Acute Kidney Injury in Patients Randomized to a Restrictive Versus Liberal Approach to Red Blood Cell Transfusion in Cardiac Surgery: A Substudy Protocol of the Transfusion Requirements in Cardiac Surgery III Noninferiority Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Garg</surname><given-names>Amit X.</given-names></name><xref ref-type="aff" rid="aff1-2054358117749532">1</xref><xref ref-type="corresp" rid="corresp1-2054358117749532"/></contrib><contrib contrib-type="author"><name><surname>Shehata</surname><given-names>Nadine</given-names></name><xref ref-type="aff" rid="aff2-2054358117749532">2</xref></contrib><contrib contrib-type="author"><name><surname>McGuinness</surname><given-names>Shay</given-names></name><xref ref-type="aff" rid="aff3-2054358117749532">3</xref></contrib><contrib contrib-type="author"><name><surname>Whitlock</surname><given-names>Richard</given-names></name><xref ref-type="aff" rid="aff4-2054358117749532">4</xref></contrib><contrib contrib-type="author"><name><surname>Fergusson</surname><given-names>Dean</given-names></name><xref ref-type="aff" rid="aff5-2054358117749532">5</xref></contrib><contrib contrib-type="author"><name><surname>Wald</surname><given-names>Ron</given-names></name><xref ref-type="aff" rid="aff6-2054358117749532">6</xref></contrib><contrib contrib-type="author"><name><surname>Parikh</surname><given-names>Chirag</given-names></name><xref ref-type="aff" rid="aff7-2054358117749532">7</xref></contrib><contrib contrib-type="author"><name><surname>Bagshaw</surname><given-names>Sean M.</given-names></name><xref ref-type="aff" rid="aff8-2054358117749532">8</xref></contrib><contrib contrib-type="author"><name><surname>Khanykin</surname><given-names>Boris</given-names></name><xref ref-type="aff" rid="aff9-2054358117749532">9</xref></contrib><contrib contrib-type="author"><name><surname>Gregory</surname><given-names>Alex</given-names></name><xref ref-type="aff" rid="aff10-2054358117749532">10</xref></contrib><contrib contrib-type="author"><name><surname>Syed</surname><given-names>Summer</given-names></name><xref ref-type="aff" rid="aff11-2054358117749532">11</xref></contrib><contrib contrib-type="author"><name><surname>Hare</surname><given-names>Gregory M. T.</given-names></name><xref ref-type="aff" rid="aff12-2054358117749532">12</xref></contrib><contrib contrib-type="author"><name><surname>Cuerden</surname><given-names>Meaghan S.</given-names></name><xref ref-type="aff" rid="aff1-2054358117749532">1</xref></contrib><contrib contrib-type="author"><name><surname>Thorpe</surname><given-names>Kevin E.</given-names></name><xref ref-type="aff" rid="aff13-2054358117749532">13</xref><xref ref-type="aff" rid="aff14-2054358117749532">14</xref></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Judith</given-names></name><xref ref-type="aff" rid="aff12-2054358117749532">12</xref></contrib><contrib contrib-type="author"><name><surname>Verma</surname><given-names>Subodh</given-names></name><xref ref-type="aff" rid="aff12-2054358117749532">12</xref></contrib><contrib contrib-type="author"><name><surname>Roshanov</surname><given-names>Pavel S.</given-names></name><xref ref-type="aff" rid="aff11-2054358117749532">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7784-2028</contrib-id><name><surname>Sontrop</surname><given-names>Jessica M.</given-names></name><xref ref-type="aff" rid="aff1-2054358117749532">1</xref></contrib><contrib contrib-type="author"><name><surname>Mazer</surname><given-names>C. David.</given-names></name><xref ref-type="aff" rid="aff12-2054358117749532">12</xref></contrib><on-behalf-of>on behalf of the Transfusion Requirements in Cardiac Surgery III (TRICS-III) investigators and the Perioperative Anesthesia Clinical Trials Group</on-behalf-of></contrib-group><aff id="aff1-2054358117749532"><label>1</label>London Health Sciences Centre, Ontario, Canada</aff><aff id="aff2-2054358117749532"><label>2</label>Mount Sinai Hospital, University of Toronto, Ontario, Canada</aff><aff id="aff3-2054358117749532"><label>3</label>Cardiothoracic and Vascular Intensive Care Unit, Auckland, New Zealand</aff><aff id="aff4-2054358117749532"><label>4</label>Population Health Research Institute, Hamilton, Ontario, Canada</aff><aff id="aff5-2054358117749532"><label>5</label>Ottawa Hospital Research Institute, Ontario, Canada</aff><aff id="aff6-2054358117749532"><label>6</label>St. Michael&#x02019;s Hospital, Toronto, Ontario, Canada</aff><aff id="aff7-2054358117749532"><label>7</label>Yale University, New Haven, Connecticut, USA</aff><aff id="aff8-2054358117749532"><label>8</label>Department of Critical Care Medicine, University of Alberta, Edmonton, Canada</aff><aff id="aff9-2054358117749532"><label>9</label>Rigshospitalet, Copenhagen University Hospital, Denmark</aff><aff id="aff10-2054358117749532"><label>10</label>Foothills Medical Centre, University of Calgary, Alberta, Canada</aff><aff id="aff11-2054358117749532"><label>11</label>McMaster University, Hamilton, Ontario, Canada</aff><aff id="aff12-2054358117749532"><label>12</label>St. Michael&#x02019;s Hospital, University of Toronto, Ontario, Canada</aff><aff id="aff13-2054358117749532"><label>13</label>Dalla Lana School of Public Health, University of Toronto, Ontario, Canada</aff><aff id="aff14-2054358117749532"><label>14</label>Applied Health Research Centre, Li Ka Shing Knowledge Institute of St. Michael&#x02019;s Hospital, Toronto, Ontario, Canada</aff><author-notes><corresp id="corresp1-2054358117749532">Amit X. Garg, Westminster Tower, London Health Sciences Centre, 800 Commissioners Road East, ELL-215, London, Ontario, Canada N6A 4G5. Email: <email>amit.garg@lhsc.on.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>5</volume><elocation-id>2054358117749532</elocation-id><history><date date-type="received"><day>18</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>31</day><month>8</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder content-type="sage">Canadian Society of Nephrology, unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by/4.0/">http://www.creativecommons.org/licenses/by/4.0/</ext-link>) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><sec id="section1-2054358117749532"><title>Background:</title><p>When safe to do so, avoiding blood transfusions in cardiac surgery can avoid the risk of transfusion-related infections and other complications while protecting a scarce resource and reducing costs. This protocol describes a kidney substudy of the Transfusion Requirements in Cardiac Surgery III (TRICS-III) trial, a multinational noninferiority randomized controlled trial to determine whether the risk of major clinical outcomes in patients undergoing planned cardiac surgery with cardiopulmonary bypass is no greater with a restrictive versus liberal approach to red blood cell transfusion.</p></sec><sec id="section2-2054358117749532"><title>Objective:</title><p>The objective of this substudy is to determine whether the risk of acute kidney injury is no greater with a restrictive versus liberal approach to red blood cell transfusion, and whether this holds true in patients with and without preexisting chronic kidney disease.</p></sec><sec id="section3-2054358117749532"><title>Design and Setting:</title><p>Multinational noninferiority randomized controlled trial conducted in 73 centers in 19 countries (2014-2017).</p></sec><sec id="section4-2054358117749532"><title>Patients:</title><p>Patients (~4800) undergoing planned cardiac surgery with cardiopulmonary bypass.</p></sec><sec id="section5-2054358117749532"><title>Measurements:</title><p>The primary outcome of this substudy is perioperative acute kidney injury, defined as an acute rise in serum creatinine from the preoperative value (obtained in the 30-day period before surgery), where an acute rise is defined as &#x02265;26.5 &#x003bc;mol/L in the first 48 hours after surgery or &#x02265;50% in the first 7 days after surgery.</p></sec><sec id="section6-2054358117749532"><title>Methods:</title><p>We will report the absolute risk difference in acute kidney injury and the 95% confidence interval. We will repeat the primary analysis using alternative definitions of acute kidney injury, including staging definitions, and will examine effect modification by preexisting chronic kidney disease (defined as a preoperative estimated glomerular filtration rate [eGFR] &#x0003c;60 mL/min/1.73 m<sup>2</sup>).</p></sec><sec id="section7-2054358117749532"><title>Limitations:</title><p>It is not possible to blind patients or providers to the intervention; however, objective measures will be used to assess outcomes, and outcome assessors will be blinded to the intervention assignment.</p></sec><sec id="section8-2054358117749532"><title>Results:</title><p>Substudy results will be reported by the year 2018.</p></sec><sec id="section9-2054358117749532"><title>Conclusions:</title><p>This substudy will provide generalizable estimates of the risk of acute kidney injury of a restrictive versus liberal approach to red blood cell transfusion in the presence of anemia during cardiac surgery done with cardiopulmonary bypass.</p></sec><sec id="section10-2054358117749532"><title>Trial Registration:</title><p><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link>; clinical trial registration number NCT 02042898.</p></sec></abstract><trans-abstract xml:lang="fr"><title>Abr&#x000e9;g&#x000e9;</title><sec id="section11-2054358117749532"><title>Contexte:</title><p>En chirurgie cardiaque, &#x000e9;viter les transfusions sanguines, lorsque s&#x000e9;curitaire, contribue &#x000e0; r&#x000e9;duire les risques d&#x02019;infections transfusionnelles et de complications tout en pr&#x000e9;servant une ressource rare et en r&#x000e9;duisant le co&#x000fb;t des soins. Ce protocole d&#x000e9;crit une &#x000e9;tude secondaire qui examine le volet des risques d&#x02019;insuffisance r&#x000e9;nale aigu&#x000eb; (IRA) de l&#x02019;&#x000e9;tude TRICS-III (Transfusion Requirements in Cardiac Surgery III), un essai de non-inf&#x000e9;riorit&#x000e9; multinational, contr&#x000f4;l&#x000e9; et &#x000e0; r&#x000e9;partition al&#x000e9;atoire faisant &#x000e9;tat des exigences applicables &#x000e0; la transfusion sanguine en chirurgie cardiaque. Notre protocole vise plus particuli&#x000e8;rement &#x000e0; d&#x000e9;terminer si le risque d&#x02019;atteintes r&#x000e9;nales encouru par les patients subissant une chirurgie de pontages coronarien est plus ou moins grand selon que l&#x02019;on pr&#x000e9;conise une approche restrictive ou lib&#x000e9;rale en mati&#x000e8;re de transfusion sanguine.</p></sec><sec id="section12-2054358117749532"><title>Objectif:</title><p>L&#x02019;objectif de notre &#x000e9;tude est de d&#x000e9;terminer si le risque d&#x02019;IRA est plus ou moins grand selon que l&#x02019;on pr&#x000e9;conise une approche restrictive ou lib&#x000e9;rale &#x000e0; l&#x02019;&#x000e9;gard de la transfusion sanguine; et, si c&#x02019;est le cas, d&#x02019;&#x000e9;tablir si ce risque diff&#x000e9;rentiel perdure selon que le patient &#x000e9;tait ou non atteint d&#x02019;insuffisance r&#x000e9;nale chronique avant l&#x02019;intervention.</p></sec><sec id="section13-2054358117749532"><title>Cadre et type d&#x02019;&#x000e9;tude:</title><p>L&#x02019;&#x000e9;tude consiste en un essai multinational de non-inf&#x000e9;riorit&#x000e9;, contr&#x000f4;l&#x000e9; et &#x000e0; r&#x000e9;partition al&#x000e9;atoire, men&#x000e9; entre 2014 et 2017 au sein de 73 centres r&#x000e9;partis dans 19 pays.</p></sec><sec id="section14-2054358117749532"><title>Patients:</title><p>L&#x02019;&#x000e9;tude compte environ 4 800 patients ayant subi un pontage coronarien.</p></sec><sec id="section15-2054358117749532"><title>Mesures:</title><p>Le principal facteur observ&#x000e9; est le d&#x000e9;veloppement d&#x02019;une IRA p&#x000e9;riop&#x000e9;ratoire, telle que d&#x000e9;finie par une hausse marqu&#x000e9;e du taux de cr&#x000e9;atinine s&#x000e9;rique par rapport &#x000e0; la valeur pr&#x000e9;op&#x000e9;ratoire (pr&#x000e9;lev&#x000e9;e dans les 30 jours pr&#x000e9;c&#x000e9;dant l&#x02019;intervention). Nous avons d&#x000e9;fini une &#x000ab; hausse marqu&#x000e9;e &#x000bb; par un taux de cr&#x000e9;atinine atteignant au moins 26,5&#x003bc;mol/L dans les 48 heures postop&#x000e9;ratoires ou son augmentation d&#x02019;au moins 50 % &#x000e0; l&#x02019;int&#x000e9;rieur des sept premiers jours.</p></sec><sec id="section16-2054358117749532"><title>M&#x000e9;thodologie:</title><p>Nous pr&#x000e9;senterons le risque diff&#x000e9;rentiel absolu d&#x02019;IRA dans un intervalle de confiance &#x000e0; 95 %. Nous r&#x000e9;p&#x000e9;terons l&#x02019;analyse primaire en alternant les d&#x000e9;finitions de l&#x02019;IRA (notamment en fonction des diff&#x000e9;rents stades) et examinerons les &#x000e9;ventuelles modifications de l&#x02019;incidence chez des patients atteints d&#x02019;une insuffisance r&#x000e9;nale pr&#x000e9;existante (d&#x000e9;finie par un DFGe pr&#x000e9;op&#x000e9;ratoire &#x000e0; moins de 60 ml/min/1,73 m<sup>2</sup>).</p></sec><sec id="section17-2054358117749532"><title>Limites de l&#x02019;&#x000e9;tude:</title><p>Il n&#x02019;est &#x000e9;videmment pas possible de proc&#x000e9;der &#x000e0; l&#x02019;insu des patients ni des fournisseurs de soins lors de l&#x02019;intervention. Toutefois, des mesures objectives seront utilis&#x000e9;es pour &#x000e9;valuer les r&#x000e9;sultats, et les &#x000e9;valuateurs ne seront aucunement au courant de la r&#x000e9;partition des cas.</p></sec><sec id="section18-2054358117749532"><title>R&#x000e9;sultats:</title><p>Les r&#x000e9;sultats de cette &#x000e9;tude secondaire seront pr&#x000e9;sent&#x000e9;s d&#x02019;ici 2018.</p></sec><sec id="section19-2054358117749532"><title>Conclusion:</title><p>Cette &#x000e9;tude secondaire fournira des estimations g&#x000e9;n&#x000e9;ralisables du risque de d&#x000e9;velopper une IRA lors d&#x02019;un pontage coronarien selon que, pour traiter l&#x02019;an&#x000e9;mie, l&#x02019;approche &#x000e0; l&#x02019;&#x000e9;gard de la transfusion sanguine soit restrictive ou lib&#x000e9;rale.</p></sec></trans-abstract><kwd-group><kwd>acute kidney injury</kwd><kwd>anemia</kwd><kwd>cardiac surgery</kwd><kwd>cardiopulmonary bypass</kwd><kwd>transfusion</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="section20-2054358117749532"><title>What was known before</title><p>Initiating transfusions at a lower level of hemoglobin substantially reduces the number of transfusions performed with no adverse impact on clinical outcomes; however, uncertainty remains in the setting of cardiac surgery where patients may have less ability to tolerate anemia.</p></sec><sec id="section21-2054358117749532"><title>What this adds</title><p>This substudy of Transfusion Requirements in Cardiac Surgery III (TRICS-III), a multinational noninferiority randomized controlled trial, will provide new knowledge on the risk of acute kidney injury of a restrictive versus liberal approach to red blood cell transfusion in the presence of anemia during cardiac surgery done with cardiopulmonary bypass.</p></sec><sec sec-type="intro" id="section22-2054358117749532"><title>Introduction</title><p>Almost 20 million cardiac surgeries are performed worldwide each year, and the period during and shortly after cardiac surgery consumes 15% to 20% of the red blood cell supply available for transfusion.<sup><xref rid="bibr1-2054358117749532" ref-type="bibr">1</xref>,<xref rid="bibr2-2054358117749532" ref-type="bibr">2</xref></sup> When safe to do so, avoiding blood transfusion in this setting protects a scarce resource, reduces costs, and avoids the risk of transfusion-related infection and other complications, which can include myocardial infarction, stroke, and acute kidney injury.<sup><xref rid="bibr3-2054358117749532" ref-type="bibr">3</xref>,<xref rid="bibr4-2054358117749532" ref-type="bibr">4</xref></sup> However, the risks of transfusion must be balanced against the risks of untreated anemia, which can compromise tissue oxygenation and also increase the risk of myocardial infarction, stroke, and acute kidney injury.<sup><xref rid="bibr5-2054358117749532" ref-type="bibr">5</xref></sup></p><p>Avoiding unnecessary red blood cell transfusions in cardiac surgery has been identified as a critical area for research.<sup><xref rid="bibr2-2054358117749532" ref-type="bibr">2</xref></sup> Emerging evidence suggests that initiating transfusions at a lower level of hemoglobin substantially reduces the number of transfusions performed with no adverse impact on clinical outcomes.<sup><xref rid="bibr4-2054358117749532" ref-type="bibr">4</xref>,<xref rid="bibr6-2054358117749532" ref-type="bibr">6</xref></sup> These data come from randomized controlled trials as it is impossible to reliably disentangle the adverse effects of anemia and red blood cell transfusion in observational studies. In controlled trials, patients were randomized to receive a restrictive versus liberal approach to transfusion initiation, where initiation occurred at a lower versus higher level of hemoglobin, typically 75 g/L versus 95 g/L, respectively.<sup><xref rid="bibr4-2054358117749532" ref-type="bibr">4</xref>,<xref rid="bibr6-2054358117749532" ref-type="bibr">6</xref></sup> Meta-analyses of trials examining these approaches have been done in the nonsurgical and surgical setting, including small trials of patients undergoing cardiac surgery. While these studies suggest that a restrictive versus liberal approach to red blood cell transfusion is safe,<sup><xref rid="bibr4-2054358117749532" ref-type="bibr">4</xref>,<xref rid="bibr6-2054358117749532" ref-type="bibr">6</xref><xref rid="bibr7-2054358117749532" ref-type="bibr"/><xref rid="bibr8-2054358117749532" ref-type="bibr"/>-<xref rid="bibr9-2054358117749532" ref-type="bibr">9</xref></sup> uncertainty remains in the setting of cardiac surgery where patients may have less ability to tolerate anemia, and where trials conducted to date have been too small to determine whether there are meaningful differences in outcomes between the 2 groups.<sup><xref rid="bibr4-2054358117749532" ref-type="bibr">4</xref>,<xref rid="bibr6-2054358117749532" ref-type="bibr">6</xref>,<xref rid="bibr8-2054358117749532" ref-type="bibr">8</xref>,<xref rid="bibr10-2054358117749532" ref-type="bibr">10</xref></sup></p><p>Prompted by the need for better evidence, the Canadian, Australian, and New Zealand governments provided funding for a noninferiority multicenter randomized controlled trial to test the hypothesis that the risk of adverse clinical outcomes from cardiac surgery with cardiopulmonary bypass is no greater with a restrictive versus liberal approach to red blood cell transfusion. The Transfusion Requirements in Cardiac Surgery III (TRICS-III) trial (NCT02042898) was launched in 2013 and includes over 4800 patients. The primary outcome of adverse events from cardiac surgery is a composite of all-cause mortality, myocardial infarction, new focal neurological deficit, and new kidney failure treated with dialysis, as assessed within 28 days of surgery or at hospital discharge, whichever comes first.</p><p>Approximately 1% of patients who undergo cardiac surgery will develop severe acute kidney injury and receive dialysis in the perioperative period. Many more patients (over 15%) will develop an important degree of acute kidney injury<sup><xref rid="bibr11-2054358117749532" ref-type="bibr">11</xref><xref rid="bibr12-2054358117749532" ref-type="bibr"/>-<xref rid="bibr13-2054358117749532" ref-type="bibr">13</xref></sup> that is not treated with dialysis but is still associated with short- and long-term mortality, a longer hospital stay, and higher health care costs.<sup><xref rid="bibr11-2054358117749532" ref-type="bibr">11</xref>,<xref rid="bibr14-2054358117749532" ref-type="bibr">14</xref><xref rid="bibr15-2054358117749532" ref-type="bibr"/><xref rid="bibr16-2054358117749532" ref-type="bibr"/>-<xref rid="bibr17-2054358117749532" ref-type="bibr">17</xref></sup> This evidence prompted us to develop a kidney substudy of the TRICS-III trial. Our substudy will test the hypothesis that the risk of perioperative acute kidney injury is no greater with a restrictive approach to red blood cell transfusion during cardiac surgery than a liberal approach. We also want to know whether this holds true in patients with and without preexisting chronic kidney disease. This protocol describes our plan to conduct these kidney substudy analyses in TRICS-III.</p><sec id="section23-2054358117749532"><title>Primary Question</title><list list-type="order" id="list1-2054358117749532"><list-item><p>Among patients undergoing planned cardiac surgery with cardiopulmonary bypass, is a restrictive approach to red blood cell transfusion noninferior to a liberal approach with respect to the risk of perioperative acute kidney injury?</p></list-item></list></sec><sec id="section24-2054358117749532"><title>Secondary Question</title><list list-type="simple" id="list2-2054358117749532"><list-item><p>2.&#x02003;Does the presence of preexisting chronic kidney disease modify the effect of a restrictive versus liberal approach to transfusion with respect to the risk of acute kidney injury?</p></list-item></list></sec></sec><sec sec-type="methods" id="section25-2054358117749532"><title>Methods</title><sec id="section26-2054358117749532"><title>The TRICS-III Trial</title><p>TRICS-III (NCT02042898) is a multinational, open-label randomized controlled trial testing 2 commonly used red blood cell transfusion approaches in high-risk patients undergoing planned cardiac surgery with cardiopulmonary bypass (recruitment period 2014 to 2017; funded by the Canadian Institutes of Health Research, the National Health and Medical Research Council of Australia, and the Health Research Council of New Zealand). The prespecified methods of this large international trial are described elsewhere (available from the authors upon request).<sup><xref rid="bibr18-2054358117749532" ref-type="bibr">18</xref></sup> Briefly, this parallel group, pragmatic, noninferiority trial was designed to evaluate whether a restrictive approach to transfusion is no worse than a liberal approach with respect to a composite primary outcome of all-cause mortality, myocardial infarction, new focal neurological deficit, and new kidney failure treated with dialysis. The primary outcome will be assessed up to postoperative day 28 or at hospital discharge, whichever comes first. Planned enrollment was 5000 patients, and the trial accrual ended in March 2017 with 5028 randomized patients across 73 centers in 19 countries (as described below, 4850 randomized participants completed surgery). The data are currently being prepared for analysis (no between-group outcome analyses have yet taken place).</p><sec id="section27-2054358117749532"><title>Randomization and intervention</title><p>Patients were identified in the preoperative anesthesia or cardiac surgery clinic or in the in-patient unit at each hospital, where informed consent was obtained. Enrolled patients were randomized to receive a restrictive or liberal approach to red blood cell transfusion. Randomization was generated centrally online by the Applied Health Research Centre at the Li Ka Shing Knowledge Institute of St. Michael&#x02019;s Hospital (Toronto, Ontario, Canada). Randomization was stratified by center using random permuted blocks of varying sizes. For the restrictive approach, transfusion was not initiated until a patient&#x02019;s hemoglobin concentration fell below 75 g/L intraoperatively and/or postoperatively in the intensive care unit or on the hospital ward. For the liberal approach, transfusion was initiated once a patient&#x02019;s hemoglobin concentration fell below 95 g/L intraoperatively or postoperatively in the intensive care unit or if it fell below 85 g/L on the ward. For each group, transfusion occurred within the following time frames of the hemoglobin trigger: within 2 hours for patients in the operating room, within 18 hours for patients in the intensive care unit, and within 40 hours for patients on the hospital ward.</p></sec></sec><sec id="section28-2054358117749532"><title>Methods Used in the TRICS-III Kidney Substudy</title><p>Ethics approval was obtained for additional renal data collection at all 73 participating centers (in 19 countries). Key aspects of the TRICS-III protocol that are relevant to the proposed kidney substudy are described below.</p></sec><sec id="section29-2054358117749532"><title>Patient Selection</title><p>Inclusion criteria for the TRICS-III main trial were as follows: adults aged 18 years or older undergoing a planned cardiac surgery with cardiopulmonary bypass, and a Preoperative European System for Cardiac Operative Risk Evaluation (EuroSCORE I) of 6 or more. Exclusion criteria were patient refusal or inability to receive blood products, involvement in the autologous predonation program, having a heart transplant, having a type of surgery solely for an insertion of a ventricular assist device, and the presence of pregnancy or lactation. Patients who were randomized but who did not undergo cardiac surgery will be excluded from the analysis (we expect ~3% of randomized patients did not undergo surgery).</p><p>The following additional exclusions will be applied to the TRICS-III kidney substudy:</p><list list-type="order" id="list3-2054358117749532"><list-item><p>Patients with preoperative end-stage kidney disease, defined as previous chronic dialysis, receipt of a kidney transplant, or an estimated glomerular filtration rate (eGFR) &#x0003c;15 mL/min per 1.73 m<sup>2</sup> (these patients will be excluded because the prevention of postoperative acute kidney injury is no longer relevant; we expect &#x0003c;2% of randomized patients to be excluded for this reason<sup><xref rid="bibr19-2054358117749532" ref-type="bibr">19</xref></sup>).</p></list-item><list-item><p>Patients missing a preoperative serum creatinine value (because preoperative serum creatinine is necessary to identify acute kidney injury, which is defined by an acute increase in serum creatinine from the preoperative value; we expect &#x0003c;1% of randomized patients will be missing a preoperative serum creatinine value).</p></list-item><list-item><p>Patients having <italic>emergency</italic> cardiac surgery will be excluded for 2 reasons: (1) They frequently have acute kidney injury or other complications prior to surgery, and so the preoperative serum creatinine may not be stable at baseline and (2) unfortunately many die, either in the operating room or shortly thereafter, before postoperative acute kidney injury develops (we expect &#x0003c;1% of randomized patients will have undergone emergency cardiac surgery).</p></list-item></list></sec><sec id="section30-2054358117749532"><title>Data Collection and Outcomes</title><p>Preoperative serum creatinine was obtained within the 30-day period before surgery, where the most recent value before surgery will serve as the baseline value. Participating sites received study funds to measure the postoperative serum creatinine on days 1, 2, 3, and 5 after surgery. To our knowledge, at participating sites, serum creatinine measurements were traceable to isotope dilution mass spectrometry. No urine output data will be used in the primary analysis of this substudy given difficulties with accurately measuring this variable outside of the intensive care unit.</p><p>The primary outcome of the TRICS-III kidney substudy is perioperative acute kidney injury, defined as an acute rise in serum creatinine from the preoperative baseline value, where an acute rise is defined as &#x02265;26.5 &#x003bc;mol/L in the first 48 hours after surgery or &#x02265;50% in the first 7 days after surgery.<sup><xref rid="bibr20-2054358117749532" ref-type="bibr">20</xref></sup> Results from an earlier cardiac study with similar enrollment criteria as TRICS-III suggests that our data collection schedule will capture most perioperative acute kidney injury events in the first 5 days of surgery; in this previously published prospective surgery study of 1219 cardiac patients, 15% of patients developed perioperative acute kidney injury (as per our definition); 13.9% of events were observed in the hours following surgery and 38.7%, 38.7%, and 8.7% of events were observed on postoperative days 1, 2 and 3, respectively.<sup><xref rid="bibr21-2054358117749532" ref-type="bibr">21</xref></sup> For this reason, our protocol provides each center funding for serum creatinine measures on days 1, 2, 3, and 5 to encourage measurement on these days in all patients; as well, any other serum creatinine measures obtained in the perioperative period as part of routine care are recorded in the trial database (recording both their value and their date). We will compare the number of serum creatinine measurements (and the postoperative days of these measurements) in each intervention group during the hospital stay to examine the potential for ascertainment bias. While health care providers in TRICS-III are aware of the intervention received, this was also the case in our analyses of acute kidney injury within a large randomized trial where coronary artery bypass surgery was done with and without a bypass pump (where there was no difference in the frequency of serum creatinine measurement between the 2 groups given how ubiquitous serum creatinine measurements are in routine care in the perioperative setting<sup><xref rid="bibr19-2054358117749532" ref-type="bibr">19</xref></sup>). We expect that less than 2% of patients will be missing serum creatinine values in the first 2 days of surgery as a result of death.</p></sec><sec id="section31-2054358117749532"><title>Statistical Power</title><p>The TRICS-III study is designed to test whether a restrictive approach to transfusion is noninferior to a liberal approach. The total required sample size for the TRICS-III kidney substudy is 3378 based on a noninferiority margin of 3.5% for an absolute risk increase in acute kidney injury with the restrictive versus liberal approach, a 1-sided alpha of 0.025, and 85% power, assuming a baseline rate of acute kidney injury of 15%, &#x0003c;2% missing data due to death, and ~85% meeting our eligibility criteria. Thus, our projected available sample size of 4074 patients for this substudy will be adequate. A noninferiority margin of 3.5% is a reasonable minimal clinically important difference; for example, in our prior analyses of acute kidney injury within a large randomized trial, coronary artery bypass surgery done without a bypass pump reduced the relative risk of acute kidney injury by 17% (95% confidence interval, 3%-28%) compared with surgery done with a bypass pump, but without evidence of better preserved kidney function, mortality, or any other relevant clinical outcome 1 year later (with a baseline rate of 15%, a relative risk increase of 17% represents an absolute risk increase of about 2.5%).<sup><xref rid="bibr19-2054358117749532" ref-type="bibr">19</xref></sup></p></sec><sec id="section32-2054358117749532"><title>Statistical Analysis</title><p>As recommended, we will conduct both per-protocol and intention-to-treat analyses<sup><xref rid="bibr22-2054358117749532" ref-type="bibr">22</xref>,<xref rid="bibr23-2054358117749532" ref-type="bibr">23</xref></sup>; however, the per-protocol analysis will be considered primary. We will report the stability of the noninferiority conclusion between the per-protocol and intention-to-treat results,<sup><xref rid="bibr22-2054358117749532" ref-type="bibr">22</xref>,<xref rid="bibr23-2054358117749532" ref-type="bibr">23</xref></sup> and congruence in results between these analyses will increase confidence in our interpretation of the findings. Per-protocol analyses are often preferred for addressing questions of noninferiority because compared with intention-to-treat analyses they reduce the risk of falsely declaring noninferiority when a meaningful difference between the effects of 2 interventions in truth exists. In contrast, intention-to-treat analyses are preferred for questions of superiority because they reduce the risk of falsely declaring superiority when the effects of the interventions are, in truth, similar. As outlined in the TRICS-III main protocol, the per-protocol analyses will exclude (1) patients whose adherence to the assigned transfusion strategy is less than 90% and/or (2) patients who withdraw from the study at any time (including withdrawal of the patient by their treating physician). Currently, we anticipate an estimated 10% of randomized participants will be excluded from the per-protocol analysis; this subgroup of patients will be examined carefully to assess the potential for bias in the per-protocol analysis. In the intention-to-treat analyses (described below), all participants will be analyzed according to their original randomized group assignment regardless of whether transfusion occurred or which transfusion approach was followed. We will report the unadjusted absolute risk difference between the 2 groups with a 95% confidence interval using the large-sample normal approximation for a difference in proportions. We will accept noninferiority if the upper limit of the 2-sided 95% confidence interval for the difference in proportions of acute kidney injury (proportion of acute kidney injury in the restrictive-approach group minus the proportion in the liberal-approach group) is less than the noninferiority margin of 3.5%. We expect that data on postoperative serum creatinine will be missing for &#x0003c;2% of participants due to death and &#x0003c;5% due to missing data. For patients who were randomized but are missing at least 1 postoperative serum creatinine value, we will use recommended model-based multiple imputation methods using all available data to impute acute kidney injury status.<sup><xref rid="bibr24-2054358117749532" ref-type="bibr">24</xref><xref rid="bibr25-2054358117749532" ref-type="bibr"/>-<xref rid="bibr26-2054358117749532" ref-type="bibr">26</xref></sup></p><sec id="section33-2054358117749532"><title>Subgroup of preexisting chronic kidney disease</title><p>Compared with patients with preserved kidney function, patients with chronic kidney disease have a higher risk of acute kidney injury, as well as higher rates of anemia, perioperative mortality, and cardiovascular events.<sup><xref rid="bibr27-2054358117749532" ref-type="bibr">27</xref><xref rid="bibr28-2054358117749532" ref-type="bibr"/><xref rid="bibr29-2054358117749532" ref-type="bibr"/><xref rid="bibr30-2054358117749532" ref-type="bibr"/><xref rid="bibr31-2054358117749532" ref-type="bibr"/>-<xref rid="bibr32-2054358117749532" ref-type="bibr">32</xref></sup> We will examine whether the presence of preexisting chronic kidney disease (primarily defined by an eGFR &#x0003c;60 mL/min/1.73 m2, with other eGFR cut-points examined in additional analysis) modifies the effect of a restrictive versus liberal approach to transfusion with respect to the risk of acute kidney injury.<sup><xref rid="bibr30-2054358117749532" ref-type="bibr">30</xref></sup> The <italic>P</italic> value for the interaction will be assessed by including the type of transfusion approach, an indicator variable for chronic kidney disease, and an interaction term (chronic kidney disease &#x000d7; type of transfusion approach) as independent variables in a regression model for binary outcome data. We will also present the absolute risk difference between intervention groups within each subgroup.</p></sec><sec id="section34-2054358117749532"><title>Other prespecified analyses</title><p>As outlined below, we will perform several supporting analyses including a complete-case analysis, an inverse probability weighted analysis, an intention-to-treat analysis, and an adjusted analysis, examining whether there is concordance with the primary analysis.<sup><xref rid="bibr24-2054358117749532" ref-type="bibr">24</xref><xref rid="bibr25-2054358117749532" ref-type="bibr"/>-<xref rid="bibr26-2054358117749532" ref-type="bibr">26</xref></sup> We will also examine death as a competing outcome and examine alternative definitions of acute kidney injury.</p></sec><sec id="section35-2054358117749532"><title>Complete-case analysis</title><p>We will perform a complete-case analysis (no use of postoperative serum creatinine imputation) restricted to patients with at least 1 postoperative serum creatinine measurement (which will be over 90% of patients in the primary analysis). We may also perform an analysis restricted to those centers with over 90% of patients with complete serum creatinine measurements.</p></sec><sec id="section36-2054358117749532"><title>Intention-to-treat analysis</title><p>The intention-to-treat analysis will follow the same analytic approach as the primary analysis, but all participants will be analyzed according to their original randomized group assignment regardless of whether transfusion occurred or which transfusion approach was followed. In addition, if noninferiority is shown, an intention-to-treat superiority comparison will be performed using a 2-sided alpha of 0.05.</p></sec><sec id="section37-2054358117749532"><title>Adjusted analysis</title><p>In our experience with CORONARY and POISE kidney substudies,<sup><xref rid="bibr19-2054358117749532" ref-type="bibr">19</xref>,<xref rid="bibr26-2054358117749532" ref-type="bibr">26</xref></sup> the unadjusted and adjusted results were virtually identical; nonetheless, we will conduct the following mixed-effects model for binary outcome data, considering center as a random effect (randomization stratum), adjusted for several prespecified factors (measured before randomization) based on their known association with acute kidney injury in the cardiac surgery setting: age (per year), sex, hemoglobin (per 10 g/L), left ventricular systolic ejection fraction categories, diabetes mellitus, treated hypertension, and eGFR (above or below 60 mL/min/1.73 m<sup>2</sup>).<sup><xref rid="bibr33-2054358117749532" ref-type="bibr">33</xref><xref rid="bibr34-2054358117749532" ref-type="bibr"/>-<xref rid="bibr35-2054358117749532" ref-type="bibr">35</xref></sup> We will report the adjusted absolute risk difference with a 95% confidence interval (the latter estimated using bootstrap methods).<sup><xref rid="bibr19-2054358117749532" ref-type="bibr">19</xref>,<xref rid="bibr36-2054358117749532" ref-type="bibr">36</xref></sup></p></sec><sec id="section38-2054358117749532"><title>Competing event of death</title><p>To determine whether the primary result is robust when the competing event of death is considered (which may influence serum creatinine measurements after surgery), we will also examine a composite outcome of acute kidney injury or death within 5 days of surgery.</p></sec><sec id="section39-2054358117749532"><title>Alternative definitions of acute kidney injury</title><p>We will repeat the primary analysis using alternative definitions of perioperative acute kidney injury including staging definitions,<sup><xref rid="bibr20-2054358117749532" ref-type="bibr">20</xref>,<xref rid="bibr37-2054358117749532" ref-type="bibr">37</xref>,<xref rid="bibr38-2054358117749532" ref-type="bibr">38</xref></sup> and assess the consistency of effect across stages of acute kidney injury based on visual inspection of point estimates and 95% confidence intervals. Despite the large sample size, these supplementary analyses for severe stages of acute kidney injury will have limited statistical power for small effects.</p></sec></sec></sec><sec id="section40-2054358117749532"><title>Recognized Limitations</title><p>The primary outcome in this kidney substudy of TRICS-III is perioperative acute kidney injury (defined as an acute rise in serum creatinine concentration from preoperative values).<sup><xref rid="bibr20-2054358117749532" ref-type="bibr">20</xref></sup> While virtually all prevention trials of acute kidney injury follow this definition, this outcome is a surrogate endpoint that may not directly impact how a patient feels, functions, or survives. Detailed information on long-term permanent kidney function after hospital discharge will not be available in this trial. Nonetheless, our primary outcome follows the current recommended standard of diagnosis of acute kidney injury.<sup><xref rid="bibr20-2054358117749532" ref-type="bibr">20</xref></sup> We will also examine whether intervention effects are consistent across stages of acute kidney injury; despite being less frequent, events of Kidney Disease: Improving Global Outcomes (KDIGO) stage 2 and stage 3 acute kidney injury are more relevant to patients and health care providers. Although it is not possible to blind patients or providers to the intervention allocation, any resulting ascertainment bias should be minimal as we have the same prespecified serum creatinine measurement schedule for patients in both groups. Furthermore, our outcomes will be objectively measured by laboratory technicians unaware of group allocation.</p></sec><sec sec-type="conclusions" id="section41-2054358117749532"><title>Conclusions</title><p>Acute kidney injury is a common and important complication of cardiac surgery. The TRICS-III kidney substudy will efficiently and reliably assess the renal effects of a restrictive versus liberal approach to red blood cell transfusion in the presence of acute anemia. It will also assess whether the effects of these approaches differ in patients with and without preexisting chronic kidney disease. Finally, this trial will provide some insights on the interplay between acute anemia, transfusions, and the risk of acute kidney injury.</p></sec></body><back><ack><p>The authors thank the Department of Medicine at Western University for providing financial support for this substudy.</p></ack><fn-group><fn fn-type="other"><p><bold>Ethics Approval and Consent to Participate:</bold> An appropriately authorized ethics committee approved the trial in all the participating centers. Written informed consent was obtained from all the participants before enrollment.</p></fn><fn fn-type="other"><p><bold>Consent for Publication:</bold> Consent for publication was obtained from all authors.</p></fn><fn fn-type="other"><p><bold>Availability of Data and Materials:</bold> Not available.</p></fn><fn fn-type="COI-statement"><p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Amit Garg is supported by the Dr Adam Linton Chair in Kidney Health Analytics and a Clinician Investigator Salary Award from the Canadian Institutes of Health Research. Gregory M. T. Hare and C. David. Mazer are the recipients of a merit award from the Department of Anesthesia, University of Toronto. Nadine Shehata is supported by the Canadian Institutes of Health Research/Canadian Blood Services New Investigator Award. Sean M. Bagshaw is supported by a Canada Research Chair in Critical Care Nephrology.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Jessica M. Sontrop <inline-graphic xlink:href="10.1177_2054358117749532-img1.jpg"/>
<ext-link ext-link-type="uri" xlink:href="http://orcid.org/0000-0001-7784-2028">http://orcid.org/0000-0001-7784-2028</ext-link></p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-2054358117749532"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chiavetta</surname><given-names>JA</given-names></name><name><surname>Herst</surname><given-names>R</given-names></name><name><surname>Freedman</surname><given-names>J</given-names></name><name><surname>Axcell</surname><given-names>TJ</given-names></name><name><surname>Wall</surname><given-names>AJ</given-names></name><name><surname>van Rooy</surname><given-names>SC.</given-names></name></person-group>
<article-title>A survey of red cell use in 45 hospitals in central Ontario, Canada</article-title>. <source>Transfusion</source>. <year>1996</year>;<volume>36</volume>:<fpage>699</fpage>-<lpage>706</lpage>.<pub-id pub-id-type="pmid">8780664</pub-id></mixed-citation></ref><ref id="bibr2-2054358117749532"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Josephson</surname><given-names>CD</given-names></name><name><surname>Glynn</surname><given-names>SA</given-names></name><name><surname>Kleinman</surname><given-names>SH</given-names></name><name><surname>Blajchman</surname><given-names>MA</given-names></name></person-group>; <collab>State-of-the Science Symposium Transfusion Medicine Committee</collab>. <article-title>A multidisciplinary &#x0201c;think tank&#x0201d;: the top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposium</article-title>. <source>Transfusion</source>. <year>2011</year>;<volume>51</volume>:<fpage>828</fpage>-<lpage>841</lpage>.<pub-id pub-id-type="pmid">21496044</pub-id></mixed-citation></ref><ref id="bibr3-2054358117749532"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reeves</surname><given-names>BC</given-names></name><name><surname>Murphy</surname><given-names>GJ.</given-names></name></person-group>
<article-title>Increased mortality, morbidity, and cost associated with red blood cell transfusion after cardiac surgery</article-title>. <source>Curr Opin Cardiol</source>. <year>2008</year>;<volume>23</volume>:<fpage>607</fpage>-<lpage>612</lpage>.<pub-id pub-id-type="pmid">18830077</pub-id></mixed-citation></ref><ref id="bibr4-2054358117749532"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carson</surname><given-names>JL</given-names></name><name><surname>Carless</surname><given-names>PA</given-names></name><name><surname>Hebert</surname><given-names>PC</given-names></name><etal>et al</etal></person-group>
<article-title>Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2012</year>;<fpage>CD002042</fpage>.<pub-id pub-id-type="pmid">22513904</pub-id></mixed-citation></ref><ref id="bibr5-2054358117749532"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Karkouti</surname><given-names>K</given-names></name><name><surname>Beattie</surname><given-names>WS</given-names></name><name><surname>Wijeysundera</surname><given-names>DN</given-names></name><etal>et al</etal></person-group>
<article-title>Hemodilution during cardiopulmonary bypass is an independent risk factor for acute renal failure in adult cardiac surgery</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2005</year>;<volume>129</volume>:<fpage>391</fpage>-<lpage>400</lpage>.<pub-id pub-id-type="pmid">15678051</pub-id></mixed-citation></ref><ref id="bibr6-2054358117749532"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carson</surname><given-names>JL</given-names></name><name><surname>Stanworth</surname><given-names>SJ</given-names></name><name><surname>Roubinian</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2016</year>;<volume>10</volume>:<fpage>CD002042</fpage>.<pub-id pub-id-type="pmid">27731885</pub-id></mixed-citation></ref><ref id="bibr7-2054358117749532"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murphy</surname><given-names>GJ</given-names></name><name><surname>Pike</surname><given-names>K</given-names></name><name><surname>Rogers</surname><given-names>CA</given-names></name><etal>et al</etal></person-group>
<article-title>Liberal or restrictive transfusion after cardiac surgery</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>
<fpage>997</fpage>-<lpage>1008</lpage>.<pub-id pub-id-type="pmid">25760354</pub-id></mixed-citation></ref><ref id="bibr8-2054358117749532"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Curley</surname><given-names>GF</given-names></name><name><surname>Shehata</surname><given-names>N</given-names></name><name><surname>Mazer</surname><given-names>CD</given-names></name><name><surname>Hare</surname><given-names>GM</given-names></name><name><surname>Friedrich</surname><given-names>JO.</given-names></name></person-group>
<article-title>Transfusion triggers for guiding RBC transfusion for cardiovascular surgery: a systematic review and meta-analysis</article-title>. <source>Crit Care Med</source>. <year>2014</year>;<volume>42</volume>:<fpage>2611</fpage>-<lpage>2624</lpage>.<pub-id pub-id-type="pmid">25167086</pub-id></mixed-citation></ref><ref id="bibr9-2054358117749532"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hajjar</surname><given-names>LA</given-names></name><name><surname>Vincent</surname><given-names>J-L</given-names></name><name><surname>Galas</surname><given-names>FRBG</given-names></name><etal>et al</etal></person-group>
<article-title>Transfusion requirements after cardiac surgery</article-title>. <source>JAMA</source>. <year>2010</year>;<volume>304</volume>:<fpage>1559</fpage>-<lpage>1567</lpage>.<pub-id pub-id-type="pmid">20940381</pub-id></mixed-citation></ref><ref id="bibr10-2054358117749532"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shehata</surname><given-names>N</given-names></name><name><surname>Mazer</surname><given-names>CD</given-names></name><name><surname>Thorpe</surname><given-names>KE.</given-names></name></person-group>
<article-title>Blood transfusion and cardiac surgery</article-title>. <source>JAMA</source>. <year>2011</year>;<volume>305</volume>:<fpage>357</fpage>-<lpage>358</lpage>.</mixed-citation></ref><ref id="bibr11-2054358117749532"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thiele</surname><given-names>RH</given-names></name><name><surname>Isbell</surname><given-names>JM</given-names></name><name><surname>Rosner</surname><given-names>MH.</given-names></name></person-group>
<article-title>AKI associated with cardiac surgery</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2015</year>;<volume>10</volume>:<fpage>500</fpage>-<lpage>514</lpage>.<pub-id pub-id-type="pmid">25376763</pub-id></mixed-citation></ref><ref id="bibr12-2054358117749532"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiers</surname><given-names>HD</given-names></name><name><surname>van den Boogaard</surname><given-names>M</given-names></name><name><surname>Schoenmakers</surname><given-names>MCJ</given-names></name><name><surname>van der Hoeven</surname><given-names>JG</given-names></name><name><surname>van Swieten</surname><given-names>HA</given-names></name><name><surname>Heemskerk</surname><given-names>S</given-names></name><name><surname>Pickkers</surname><given-names>P.</given-names></name></person-group>
<article-title>Comparison and clinical suitability of eight prediction models for cardiac surgery-related acute kidney injury</article-title>. <source>Nephrol Dial Transplant</source>. <year>2013</year>;<volume>28</volume>:<fpage>345</fpage>-<lpage>351</lpage>.<pub-id pub-id-type="pmid">23222415</pub-id></mixed-citation></ref><ref id="bibr13-2054358117749532"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosner</surname><given-names>MH</given-names></name><name><surname>Okusa</surname><given-names>MD.</given-names></name></person-group>
<article-title>Acute kidney injury associated with cardiac surgery</article-title>. <source>Clin J Am Soc Nephrol</source>. <year>2006</year>;<volume>1</volume>:<fpage>19</fpage>-<lpage>32</lpage>.<pub-id pub-id-type="pmid">17699187</pub-id></mixed-citation></ref><ref id="bibr14-2054358117749532"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ricci</surname><given-names>Z</given-names></name><name><surname>Cruz</surname><given-names>D</given-names></name><name><surname>Ronco</surname><given-names>C.</given-names></name></person-group>
<article-title>The RIFLE criteria and mortality in acute kidney injury: a systematic review</article-title>. <source>Kidney Int</source>. <year>2008</year>;<volume>73</volume>:<fpage>538</fpage>-<lpage>546</lpage>.<pub-id pub-id-type="pmid">18160961</pub-id></mixed-citation></ref><ref id="bibr15-2054358117749532"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dasta</surname><given-names>JF</given-names></name><name><surname>Kane-Gill</surname><given-names>SL</given-names></name><name><surname>Durtschi</surname><given-names>AJ</given-names></name><name><surname>Pathak</surname><given-names>DS</given-names></name><name><surname>Kellum</surname><given-names>JA.</given-names></name></person-group>
<article-title>Costs and outcomes of acute kidney injury (AKI) following cardiac surgery</article-title>. <source>Nephrol Dial Transplant</source>. <year>2008</year>;<volume>23</volume>:<fpage>1970</fpage>-<lpage>1974</lpage>.<pub-id pub-id-type="pmid">18178605</pub-id></mixed-citation></ref><ref id="bibr16-2054358117749532"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Burdick</surname><given-names>E</given-names></name><name><surname>Honour</surname><given-names>M</given-names></name><name><surname>Bonventre</surname><given-names>JV</given-names></name><name><surname>Bates</surname><given-names>DW.</given-names></name></person-group>
<article-title>Acute kidney injury, mortality, length of stay, and costs in hospitalized patients</article-title>. <source>J Am Soc Nephrol</source>. <year>2005</year>;<volume>16</volume>:<fpage>3365</fpage>-<lpage>3370</lpage>.<pub-id pub-id-type="pmid">16177006</pub-id></mixed-citation></ref><ref id="bibr17-2054358117749532"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishani</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>D</given-names></name><name><surname>Clothier</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>The magnitude of acute serum creatinine increase after cardiac surgery and the risk of chronic kidney disease, progression of kidney disease, and death</article-title>. <source>Arch Intern Med</source>. <year>2011</year>;<volume>171</volume>:<fpage>226</fpage>-<lpage>233</lpage>.<pub-id pub-id-type="pmid">21325112</pub-id></mixed-citation></ref><ref id="bibr18-2054358117749532"><label>18</label><mixed-citation publication-type="gov">
<collab>ClinicalTrials.gov</collab>. <article-title>Transfusion Requirements in Cardiac Surgery III (TRICS-III)</article-title> (NCT02042898). <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02042898">https://clinicaltrials.gov/ct2/show/NCT02042898</ext-link>. <comment>Accessed December 7, 2017</comment>.</mixed-citation></ref><ref id="bibr19-2054358117749532"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garg</surname><given-names>AX</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>311</volume>:<fpage>2191</fpage>-<lpage>2198</lpage>.<pub-id pub-id-type="pmid">24886787</pub-id></mixed-citation></ref><ref id="bibr20-2054358117749532"><label>20</label><mixed-citation publication-type="journal">
<collab>Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group</collab>. <article-title>KDIGO clinical practice guideline for acute kidney injury</article-title>. <source>Kidney Int Suppl</source>. <year>2012</year>;<volume>2</volume>:<fpage>1</fpage>-<lpage>138</lpage>.</mixed-citation></ref><ref id="bibr21-2054358117749532"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parikh</surname><given-names>CR</given-names></name><name><surname>Coca</surname><given-names>SG</given-names></name><name><surname>Thiessen-Philbrook</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery</article-title>. <source>J Am Soc Nephrol</source>. <year>2011</year>;<volume>22</volume>:<fpage>1748</fpage>-<lpage>1757</lpage>.<pub-id pub-id-type="pmid">21836143</pub-id></mixed-citation></ref><ref id="bibr22-2054358117749532"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Jarvis</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>JA</given-names></name><name><surname>Ebbutt</surname><given-names>AF.</given-names></name></person-group>
<article-title>Trials to assess equivalence: the importance of rigorous methods</article-title>. <source>BMJ</source>. <year>1996</year>;<volume>313</volume>:<fpage>36</fpage>-<lpage>39</lpage>.<pub-id pub-id-type="pmid">8664772</pub-id></mixed-citation></ref><ref id="bibr23-2054358117749532"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kaul</surname><given-names>S</given-names></name><name><surname>Diamond</surname><given-names>GA.</given-names></name></person-group>
<article-title>Good enough: a primer on the analysis and interpretation of noninferiority trials</article-title>. <source>Ann Intern Med</source>. <year>2006</year>;<volume>145</volume>:<fpage>62</fpage>-<lpage>69</lpage>.<pub-id pub-id-type="pmid">16818930</pub-id></mixed-citation></ref><ref id="bibr24-2054358117749532"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Little</surname><given-names>RJ</given-names></name><name><surname>D&#x02019;Agostino</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>ML</given-names></name><etal>et al</etal></person-group>
<article-title>The prevention and treatment of missing data in clinical trials</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>367</volume>:<fpage>1355</fpage>-<lpage>1360</lpage>.<pub-id pub-id-type="pmid">23034025</pub-id></mixed-citation></ref><ref id="bibr25-2054358117749532"><label>25</label><mixed-citation publication-type="web">
<person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>JR</given-names></name><name><surname>Kenward</surname><given-names>MG.</given-names></name></person-group>
<article-title>Missing data in randomised controlled trials&#x02014;a practical guide</article-title>. <year>2007</year>
<ext-link ext-link-type="uri" xlink:href="https://pdfs.semanticscholar.org/e9c4/6359114e7eb6fd17d3ff93fec7ce54479ef5.pdf">https://pdfs.semanticscholar.org/e9c4/6359114e7eb6fd17d3ff93fec7ce54479ef5.pdf</ext-link>. <comment>Accessed February 7, 2017</comment>.</mixed-citation></ref><ref id="bibr26-2054358117749532"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Garg</surname><given-names>AX</given-names></name><name><surname>Kurz</surname><given-names>A</given-names></name><name><surname>Sessler</surname><given-names>DI</given-names></name><etal>et al</etal></person-group>
<article-title>Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2014</year>;<volume>312</volume>:<fpage>2254</fpage>-<lpage>2264</lpage>.<pub-id pub-id-type="pmid">25399007</pub-id></mixed-citation></ref><ref id="bibr27-2054358117749532"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wijeysundera</surname><given-names>DN</given-names></name><name><surname>Karkouti</surname><given-names>K</given-names></name><name><surname>Dupuis</surname><given-names>J-Y</given-names></name><etal>et al</etal></person-group>
<article-title>Derivation and validation of a simplified predictive index for renal replacement therapy after cardiac surgery</article-title>. <source>JAMA</source>. <year>2007</year>;<volume>297</volume>:<fpage>1801</fpage>-<lpage>1809</lpage>.<pub-id pub-id-type="pmid">17456822</pub-id></mixed-citation></ref><ref id="bibr28-2054358117749532"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Palomba</surname><given-names>H</given-names></name><name><surname>de Castro</surname><given-names>I</given-names></name><name><surname>Neto</surname><given-names>ALC</given-names></name><name><surname>Lage</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name></person-group>
<article-title>Acute kidney injury prediction following elective cardiac surgery: AKICS Score</article-title>. <source>Kidney Int</source>. <year>2007</year>;<volume>72</volume>:<fpage>624</fpage>-<lpage>631</lpage>.<pub-id pub-id-type="pmid">17622275</pub-id></mixed-citation></ref><ref id="bibr29-2054358117749532"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Ordo&#x000f1;ez</surname><given-names>JD</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><name><surname>Go</surname><given-names>AS.</given-names></name></person-group>
<article-title>The risk of acute renal failure in patients with chronic kidney disease</article-title>. <source>Kidney Int</source>. <year>2008</year>;<volume>74</volume>:<fpage>101</fpage>-<lpage>107</lpage>.<pub-id pub-id-type="pmid">18385668</pub-id></mixed-citation></ref><ref id="bibr30-2054358117749532"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chawla</surname><given-names>LS</given-names></name><name><surname>Kimmel</surname><given-names>PL.</given-names></name></person-group>
<article-title>Acute kidney injury and chronic kidney disease: an integrated clinical syndrome</article-title>. <source>Kidney Int</source>. <year>2012</year>;<volume>82</volume>:<fpage>516</fpage>-<lpage>524</lpage>.<pub-id pub-id-type="pmid">22673882</pub-id></mixed-citation></ref><ref id="bibr31-2054358117749532"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Go</surname><given-names>AS</given-names></name><name><surname>Chertow</surname><given-names>GM</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name><name><surname>McCulloch</surname><given-names>CE</given-names></name><name><surname>Hsu</surname><given-names>CY.</given-names></name></person-group>
<article-title>Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>:<fpage>1296</fpage>-<lpage>1305</lpage>.<pub-id pub-id-type="pmid">15385656</pub-id></mixed-citation></ref><ref id="bibr32-2054358117749532"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tonelli</surname><given-names>M</given-names></name><name><surname>Wiebe</surname><given-names>N</given-names></name><name><surname>Culleton</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Chronic kidney disease and mortality risk: a systematic review</article-title>. <source>J Am Soc Nephrol</source>. <year>2006</year>;<volume>17</volume>:<fpage>2034</fpage>-<lpage>2047</lpage>.<pub-id pub-id-type="pmid">16738019</pub-id></mixed-citation></ref><ref id="bibr33-2054358117749532"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thakar</surname><given-names>CV</given-names></name><name><surname>Arrigain</surname><given-names>S</given-names></name><name><surname>Worley</surname><given-names>S</given-names></name><name><surname>Yared</surname><given-names>JP</given-names></name><name><surname>Paganini</surname><given-names>EP.</given-names></name></person-group>
<article-title>A clinical score to predict acute renal failure after cardiac surgery</article-title>. <source>J Am Soc Nephrol</source>. <year>2005</year>;<volume>16</volume>:<fpage>162</fpage>-<lpage>168</lpage>.<pub-id pub-id-type="pmid">15563569</pub-id></mixed-citation></ref><ref id="bibr34-2054358117749532"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kolli</surname><given-names>H</given-names></name><name><surname>Rajagopalam</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Mild acute kidney injury is associated with increased mortality after cardiac surgery in patients with eGFR &#x0003c; 60 mL/min/1.73 m(2)</article-title>. <source>Ren Fail</source>. <year>2010</year>;<volume>32</volume>:<fpage>1066</fpage>-<lpage>1072</lpage>.<pub-id pub-id-type="pmid">20863211</pub-id></mixed-citation></ref><ref id="bibr35-2054358117749532"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alkhunaizi</surname><given-names>AM</given-names></name><name><surname>Shah</surname><given-names>SSA</given-names></name><name><surname>Wesslen</surname><given-names>US</given-names></name><name><surname>Al Sadah</surname><given-names>ZA</given-names></name><name><surname>Antony</surname><given-names>A.</given-names></name></person-group>
<article-title>Acute kidney injury after cardiac surgery in eastern Saudi Arabia</article-title>. <source>East Mediterr Health J</source>. <year>2011</year>;<volume>17</volume>:<fpage>495</fpage>-<lpage>500</lpage>.<pub-id pub-id-type="pmid">21796967</pub-id></mixed-citation></ref><ref id="bibr36-2054358117749532"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Austin</surname><given-names>PC.</given-names></name></person-group>
<article-title>Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model</article-title>. <source>J Clin Epidemiol</source>. <year>2010</year>;<volume>63</volume>:<fpage>2</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">19230611</pub-id></mixed-citation></ref><ref id="bibr37-2054358117749532"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bellomo</surname><given-names>R</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Palevsky</surname><given-names>P</given-names></name></person-group>; <collab>Acute Dialysis Quality Initiative Workgroup</collab>. <article-title>Acute renal failure&#x02014;definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group</article-title>. <source>Crit Care</source>. <year>2004</year>;<volume>8</volume>:<fpage>R204</fpage>-<lpage>R112</lpage>.<pub-id pub-id-type="pmid">15312219</pub-id></mixed-citation></ref><ref id="bibr38-2054358117749532"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RL</given-names></name><name><surname>Kellum</surname><given-names>JA</given-names></name><name><surname>Shah</surname><given-names>SV</given-names></name><etal>et al</etal></person-group>
<article-title>Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury</article-title>. <source>Crit Care</source>. <year>2007</year>;<volume>11</volume>:<fpage>R31</fpage>.<pub-id pub-id-type="pmid">17331245</pub-id></mixed-citation></ref></ref-list></back></article>